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A B S T R A C T   
Background: The emergence and spread of multidrug-resistant organisms (MDROs) represent a threat to human 
and animal health. 
Objectives: To assess duration of carriage of MDROs in dogs and cats presented to veterinary clinics/hospitals in 
Switzerland. To estimate prevalence, duration of and risk factors for MDRO carriage in their owners and the 
occurrence of co-carriage in owner-pet pairs. 
Methods: Prospective, longitudinal, observational study. Nasal swabs and fecal samples were collected from 50 
owners of dogs and cats presented to 3 large veterinary hospitals, 1 medium-sized clinic and 1 practice. If pet or 
owner tested positive for a MDRO, follow-up samples were collected for up to 8 months. Methicillin-resistant 
(MR) Staphylococcus aureus, MR S. pseudintermedius, MR coagulase-negative staphylococci (MRCoNS), MR 
Macrococcus spp., cephalosporinase- and carbapenemase-producing (CP) Enterobacterales were isolated and 
further characterized by MALDI-TOF MS, microdilution, β-lactam resistance gene detection, REP/ERIC-PCR, 
multilocus sequence typing or whole-genome sequencing. Risk factors for MDRO carriage in owners were 
explored based on questionnaire-derived data. 
Results: Five out of 50 owners carried 3rd generation cephalosporin-resistant Enterobacterales (3GC-R-Ent.), and 
5/50 MRCoNS. In 3 dogs and 4 cats carriage of 3GC-R-Ent. persisted for up to 136 days after discharge (median 
99 days, IQR 83 days, range 36–136 days), in two cats isolates were carbapenem-resistant. Owner-pet co-carriage 
was not observed. No specific risk factors for MDRO carriage in owners were identified. 
Conclusions: After discharge from veterinary care, dogs and cats may carry 3GC-R-Ent. for prolonged time pe-
riods. Carriage of MDROs was common in owners, but pet-owner co-carriage of the same MDRO was not 
observed.  
Abbreviations: AMR, Antimicrobial resistance; 3GC-R, Third Generation Cephalosporin-resistant; 3GC-R-Ent., Third Generation Cephalosporin-resistant Enter-
obacterales; CI, Confidence interval; COL-R, Colistin-resistant; CP, Carbapenemase-producing; CR, Carbapenem-resistant; CRE, Carbapenem-resistant Enter-
obacterales; CLSI, Clinical and Laboratory Standards Institute; ERIC-PCR, Enterobacterial repetitive intergenic consensus polymerase chain reaction; ESBL, Extended 
spectrum β-lactamase; ESBL-E. coli, ESBL-producing Escherichia coli; ESBL-KP, ESBL-producing Klebsiella pneumoniae; EUCAST, European Committee on Antimicrobial 
Susceptibility Testing; IQR, Interquartile range; KP, Klebsiella pneumoniae; MALDI-TOF MS, Matrix-assisted laser desorption/ionization time of flight mass spec-
trometry; MDR, Multidrug-resistant; MDROs, Multidrug-resistant organisms; MICs, Minimal inhibitory concentrations; MLST, Multilocus sequence typing; MR, 
Methicillin-resistant; MRCoNS, Methicillin-resistant coagulase-negative staphylococci; MRSA, Methicillin-resistant Staphylococcus aureus; MRSP, Methicillin-resistant 
Staphylococcus pseudintermedius; pAmpC, Plasmid-encoded AmpC; REP-PCR, Repetitive element palindromic polymerase chain reaction; ST, Sequence type; TMP-S, 
Trimethoprim/sulfamethoxazole; WGS, Whole-genome sequencing. 
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1. Introduction 
Antimicrobial resistance (AMR) is a threat to both human and animal 
health. Bacteria are considered multi-drug resistant if they have ac-
quired non-susceptibility to at least one agent in three or more antimi-
crobial categories [1]. Dogs and cats are considered family members in 
many households and may be a source of multidrug-resistant organisms 
(MDROs) [2]. Dogs and cats share the owner’s living space and outdoor 
environment and exchange affectionate behaviours with their owners 
which commonly involve very close physical contact or contact with 
saliva [3]. In a recent study from Belgium, 98.3% of respondents indi-
cated that highly intense interactions such as licking of the owner’s face 
or hands and eating from the owner’s plate occurred at least sometimes 
[4]. While a close emotional connection with their pet benefits the 
owner’s physical and mental wellbeing [5,6], such high intensity in-
teractions may lead to the transmission of microorganisms, in particular 
those residing on the skin, on mucosal surfaces [7] or in the intestinal 
tract [8]. 
Due to the close human-animal bond, pets also benefit from 
advanced hospital care in case of illness or accident. Like human hos-
pitals, veterinary hospital environments favor the selection and trans-
mission of MDROs due to a high density of susceptible patients and the 
selective pressure exerted by the use of broad acting antimicrobials [9]. 
During their hospitalization, small animal patients may therefore ac-
quire MDROs [10,11]. Understanding the risk of cross-species transfer of 
MDROs or relevant resistance genes between MDRO carrying pets and 
their owners is a central element when tacking the One Health aspects of 
AMR [8,12–14]. 
As part of a large multicenter project to assess the role of companion 
animal medicine in the selection and dissemination of MDROs, we 
recently reported a high rate of acquisition of 3rd generation 
cephalosporin-resistant Enterobacterales (3GC-R-Ent.) by cats and dogs 
in veterinary hospitals in Switzerland [11]. Acquisition of genetically 
closely related 3GC-R-Ent. and carbapenem-resistant (CR) Escherichia 
coli (Sequence type [ST]410; blaOXA181-positive) in a subset of cats and 
dogs included in that investigation was recently reported [10]. 
In this part of the project, we explored the duration of carriage of 
MDROs in dogs and cats in veterinary care and determined potential co- 
carriage of the same MDROs as well as the prevalence, duration and risk 
factors of MDRO carriage in their owners. 
2. Materials and methods 
2.1. Ethics statement 
Ethical approval for collection of samples and data from humans, 
cats and dogs was obtained from the regional Ethics Committees on 
research involving humans (Ref. 2018–00866) and the Veterinary Office 
(Ref. BE 16/18) as required. Written consent for collection of oronasal 
and rectal swabs/stool samples and the use of patient and pseudony-
mized questionnaire-derived data was obtained from owners before 
enrolment in the study. For pseudonymization, the names of animals 
and owners were replaced by enrolment codes. Study data were 
collected and managed using the Research Electronic Data Capture 
system (REDCap) hosted at the University of Bern [15,16]. 
2.2. Study design and setting 
This investigation was part of a prospective multi-center longitudinal 
observational study to elucidate the role of veterinary hospitals in the 
selection and spread of MDROs. The study was conducted in Switzerland 
between May 2018 and March 2019 at 3 large referral hospitals (clinics 
1–3), 1 medium-sized clinic (clinic 4) and a small practice delivering 
predominantly outpatient care (practice 1). 
At presentation of their animal to a veterinary clinic or practice 
owners were invited to participate in the study by filling in a pet- 
centered and owner-centered risk-factor questionnaire and by submit-
ting nasal swabs and fecal samples for culture. In addition, their dogs 
and cats were sampled via oro-nasal and rectal swabs at presentation 
and discharge from the veterinary hospitals as previously described 
[11]. If either owner or pet carried a MDRO, owners were invited to 
participate in a follow-up study, which foresaw monthly resampling 
until at least two negative results had been obtained. The three parts of 
the study presented here and the populations of dogs, cats and owners 
enrolled in the different parts of the study are shown in Fig. 1 (Study 
design). 
2.3. Data collection 
2.3.1. Questionnaire 
Participating owners were given a hardcopy and a link to the ques-
tionnaire [11]. The owner-centered questionnaire retrieved de-
mographic, lifestyle and general health data, dietary habits, current or 
previous medical treatments, travel history and exposure to farm ani-
mals as well as questions assessing the closeness of the contact between 
owners and their animals, such as sharing the same bed. The results of 
the animal-centered questionnaire and their association with MDRO 
carriage have been previously reported [11]. 
2.3.2. Sampling 
Owners were given detailed instructions and written information on 
how to perform their own nasal swabbing and stool sample collection. 
They also performed the follow-up oronasal and rectal sampling of their 
pet as previously described [11]. Rectal and oronasal swabs were 
collected with dry sterile swabs with Amies transport medium (Sarstedt 
AG & Co. KG, Nümbrecht, Germany). Swabs and fecal samples were sent 
to the laboratory (IFIK Bern) in padded envelopes with pre-paid priority 
shipping. 
2.3.3. Isolation and identification of bacteria 
Bacteria were isolated and identified as previously described 
[10,17]. Briefly, rectal swabs and fecal samples were tested for the 
presence of Gram-negative MDROs. Swabs were placed into 5 ml of non- 
selective Luria-Bertani (LB) enrichment broth at 37 ◦C for 24 h. A loopful 
of the culture was then streaked onto ChromID® extended spectrum 
β-lactamase (ESBL) plates to select for 3GC-R, or ChromID® OXA-48 and 
ChromID® CARBA plates (bioMérieux SA, Marcy-l’Étoile, France) to 
select for CR bacteria. Plates were incubated at 37 ◦C for 24 h under 
aerobic conditions. Colonies were sub-cultivated onto tryptone soy agar 
plates containing 5% sheep blood (TSA-S; Becton & Dickinson Company, 
Franklin Lakes, USA). Carbapenemase production was assessed using 
the Blue-Carba test [18]. 
Oro-nasal swabs were tested for the presence of methicillin-resistant 
(MR) staphylococci and macrococci using a two-step selective enrich-
ment followed by selection on MR Staphylococcus (S.) aureus (MRSA) 
selective agar (BBL CHROMagar MRSA II, Becton, Dickinson and Com-
pany) at 37 ◦C for 24 h. 
Isolates were identified to the species level using matrix-assisted 
laser desorption/ionization time of flight mass spectrometry (MALDI- 
TOF MS) analysis (Bruker Daltonics GmbH, Bremen, Germany). Further 
characterization of human MR staphylococci including antimicrobial 
susceptibility testing, sequence typing and identification of mecA was 
only performed for 2/6 isolates. 
2.3.4. Antimicrobial susceptibility testing 
Minimal inhibitory concentrations (MICs) of a panel of antimicro-
bials were determined by broth microdilution using Sensititre EUST, 
EUVSEC, EUVSEC2 and GNX2F plates (Thermo Fisher Scientific, Wal-
tham, USA) following guidelines by the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) and the Clinical and 
Laboratory Standards Institute (CLSI) [19,20]. 
Extended spectrum β-lactamase and carbapenemase genes were 
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identified using the new CT103XL microarray (Check-Points, Wage-
ningen, The Netherlands [21]). Prior to whole genome sequencing 
(WGS), carbapenemase-producing (CP) isolates were tested for the 
presence of blaOXA-48-like genes by PCR [22]. The methicillin resistance 
genes mecA, mecB, and mecD were identified by PCR as previously 
described [23–25]. 
2.3.5. Rep-PCR and whole genome sequencing 
Genetic relationships and clonality between isolates of the same 
species were determined by Repetitive element palindromic/entero-
bacterial repetitive intergenic consensus polymerase chain reaction 
(REP/ERIC-PCR) [26,27] and multilocus sequence typing (MLST) for 
MRSA, MR Staphylococcus pseudintermedius (MRSP), MR coagulase- 
negative staphylococci (MRCoNS), MR Macrococcus spp. using the cor-
responding schemes published in the pubMLST database (https://pub 
mlst.org/databases/) and for colistin-resistant (COL-R), ESBL- 
producing and CP Enterobacterales using the Center for Genomic 
Epidemiology (http://www.genomicepidemiology.org/). Fifteen Gram- 
negative E. coli strains from dogs and cats included in this part of the 
study and six E. coli isolates from owners were further characterized via 
WGS. Whole genome sequencing was used to confirm the identity of 
selected isolates and the presence of specific resistance genes. 
2.4. Statistical methods 
Statistical analysis was performed using the NCSS® program 
(NCSS11 Statistical Software. 2016. NCSS, LLC, Kaysville, Utah, USA. 
ncss.com/software/ncss). 
The overall prevalence of MDRO carriage in owners was calculated 
with a 95% confidence interval (CI). Acquisition was defined as the 
presence of a genetically unrelated MDRO species or strain in follow-up 
samples. Persistence was defined as isolation of MDROs with matching 
molecular profiles (REP-PCR, WGS) and antimicrobial resistance pro-
files from repeated samples of the same individual. 
Associations between MDRO carriage in owners and specific 
questionnaire-derived variables were examined using univariable 
regression analysis. As no variables with a p-value of <0.1 were iden-
tified, multivariable models could not be built. 
If either owner or her/his pet carried MDRO, the total number of 
contact days (days after hospital release of the animal until the last 
sampling time point) was calculated in order to estimate opportunities 
for transmission. 
3. Results 
3.1. Study populations 
3.1.1. Pet owners 
A total of 50 owners belonging to 46 households provided nasal and 
stool samples and 38 (76%; 95%CI, 61.8–86.9) of them filled in the 
questionnaire. 
Demographic and questionnaire-derived owner data are shown in 
Supplemental Table 1. The median age of participating owners was 50 
years (interquartile range [IQR] 17; range 25–79 days); 21 (55.3%; 95% 
CI, 28.2–56.8) owners were women and 17 (44.7%; 95%CI, 21.2–48.8) 
were men. There was an equal distribution of owners living in cities, 
small towns and the countryside. The majority of owners (73.7%) lived 
in the proximity (<1 km) of at least one farm and 71.1% had received 
antimicrobial therapy in the past two years. Of the 38 respondents, 2 
(5.3%) worked in the human healthcare system and 30 (79%) had been 
in contact with the healthcare system (as patients) in the past 12 months. 
None of the respondents had been diagnosed with MDRO infections in 
the past two years. 
3.1.2. Dogs and cats 
A total of 271 animals including 183 (67.5%) dogs and 88 (32.5%) 
cats were enrolled in the original screening study. Of these, 34 MDRO- 
positive animals (25 dogs, 9 cats) were included in the study on 
MDRO pos dogs (11)
no owner follow-up 
available
271 dogs and cats presented to 5 veterinary 
pracces/clinics and their owners
50 Owners/46 households
- Completed quesonnaires (38)
- Nasal swabs (48)
- Fecal samples (49)
MDROs detected in 9 (18%) owners 
Prevalence and risk factors for 
acquision of MDRO study11
MDRO pos cats (4)
no owner follow-up 
available
Prevalence and risk factors for 
MDRO carriage in owners
Owner-pet co-colonizaon (n=21)
Duraon of MDRO carriage in dogs and cats (n=34)
Owner-Dog pairs
Only dog MDRO pos (12)
MDRO pos dog + owner (2)
Owner-Cat pairs
Only cat MDRO pos (5)
Only owner MDRO pos (0)
MDRO pos cat + owner (0)
Only owner MDRO pos  (2)
MDRO pos dog+owner (1)
Owner-Dog pairs
Fig. 1. Study design. Out of a population of 271 animals enrolled in a large prevalence study, 25 dogs and 9 cats, which had tested positive for MDRO carriage and 2 
dogs belonging to a MDRO positive owner were followed up by nasal and rectal swabbing for up to 8 months. 50 owners of animals participating in this study 
submitted nasal swabs and/or fecal samples, 38 submitted questionnaires. Five owner-cat pairs and 16 owner-dog pairs were followed to monitor for co-colonization. 
The part of this study in the grey box has been previously reported [11]. 
Abbreviations: MDROs, multidrug-resistant organisms. 
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duration of carriage and 21 pet-owner pairs were included in the co- 
carriage study (Fig. 1). 
Demographic, hospitalization and treatment data of the 37 animals 
included in the follow-up and co-carriage study are shown in Table 1. Of 
the 28 dogs, 6 dogs were mixed breeds and 22 pure breeds, belonging to 
19 different breeds, the most common being cotton de Tuléar (n = 2), 
Jack Russell Terrier (n = 2) and French Bulldog (n = 2). All dogs were 
family dogs and slept in the owner’s bed. Of the 9 cats, 4 were European 
shorthaired, and one each of the following, Maine Coon, Persian, Sibe-
rian, Exotic long haired and Bengal. All cats slept in or on their owner’s 
beds. 
A subgroup of 7/34 (21%; 95%CI, 8.7–37.9) pets included in the 
duration of carriage study showed long-term carriage of 3GC-R-Ent. 
(>30 days; Fig. 2). These animals had a broad range of underlying 
clinical problems. Five animals had been treated with potentiated ami-
nopenicillins, one with fluoroquinolone and 1 had not been treated with 
antibiotics. There was no significant association between duration of 
antimicrobial treatments, antimicrobial class and MDRO persistence. 
3.1.3. Prevalence, MDRO isolates and risk factors for MDRO carriage in 
owners 
MDROs were isolated in 9/50 owners (18%; 95%CI, 8.6–31.4) at any 
sampling time point during the study period. 
ESBL-producing E. coli (ESBL-E. coli) (producing CTX-M-55, n = 2; 
CTX-M-15, n = 2) were isolated from fecal samples of four owners. A 
further 4 owners showed nasal colonization with MRCoNS 
(S. epidermidis n = 2; S. haemolyticus n = 2). In one family member (149 
B), MRSA (ST97) and a fecal CTX-M-1-producing E. coli were isolated. At 
follow up 3 months later, the owner carried a nasal MR S. warneri and a 
different fecal E. coli strain (producing a CTX-M-14/− 24-like). The 
person was healthy, did not work in the healthcare sector and had no 
history of international travel. A second person in the same household 
tested negative for MDRO on a single sample. 
The full list of variables included in the risk factor analysis are shown 
in Supplemental Table 1. None of the variables were significantly 
associated with MDRO carriage in owners. Details and MICs of isolates 
are shown in Supplemental Tables 2 and 3. 
3.1.4. Duration of MDRO carriage in dogs and cats 
A subgroup of 34 MDRO-positive pets were followed up for a median 
duration of 150 days (IQR 58; range 45–247 days). Of these, 7 dogs and 
3 cats carried MR Gram-positive bacteria (8 MR staphylococci and 1 MR 
Macrococcus (M.) canis) oro-nasally. In 12 dogs and 4 cats, one 3GC-R- 
Ent. strain was isolated from a rectal swab. In 8 dogs and 2 cats, 3GC- 
R-Klebsiella pneumoniae (KP) and E. coli were co-isolated. MR staphylo-
cocci and 3GC-R-Ent. were isolated simultaneously in 1 cat. The details 
of the 3GC-R-Ent. isolates from animals included in this study are shown 
in Supplemental Tables 4 and 5. 
The median time between discharge and first follow-up was 81 days 
(IQR 32, range 34–164 days). No persistence was found in any of the 10 
animals carrying MR Staphylococcus spp. or MR-M. canis when resam-
pled between 60 and 164 days after discharge. 
Of the 27 animals carrying 3GC-R-Ent. at discharge, 7 were still 
carrying one (n = 6) or two (n = 1) 3GC-R-Ent. isolates at their first 
recheck 36 to 99 days after discharge: 3 of them carried ESBL-producing 
KP (ESBL-KP) (26, 59,148), 3 an ESBL-E. coli (69, 76, 253) and 1 cat both 
microorganisms (96). The second follow-up was obtained from 22 of the 
27 animals, and only 3 animals still carried one 3GC-R-Ent. isolates (26, 
59, 69). In the third and the fourth follow-up, no MDROs were isolated 
anymore. Sampling time points, duration of carriage and isolates of dogs 
and cats carrying MDRO beyond 30 days are shown in Fig. 2. Details of 
all animals included in the study are shown in Supplemental Figs. 1–3. 
3.1.5. Antimicrobial resistance profiles 
MICs for all isolates included in the study are shown in Supplemental 
Tables 2–5. Human E. coli isolates showed an ESBL phenotype and be-
sides their resistance to 3GC (6/6), were resistant to β-lactam antibiotics 
(4/6), trimethoprim/sulfamethoxazole (4/6), aminoglycosides (2/6), 
fluoroquinolones (2/6) and tetracyclines (2/6). None of the isolates 
showed resistance to carbapenems or colistin. 
The resistance profiles of the two MR Staphylococcus isolates that 
were further characterized are shown in Supplemental Table 3. 
Antimicrobial resistance profiles of the Gram-negative MDROs iso-
lated at discharge from dogs and cats have been previously reported 
[11]. These are shown again in Supplemental Tables 4 and 5 as starting 
point for the follow-up study. 
3.1.6. Molecular epidemiology/relatedness of the MDROs 
The bacteriologic profiles of all Gram-negative isolates found in pets 
included in this investigation are listed in Supplemental Tables 4 and 5. 
In 4 animals 3GC-R-KP were repeatedly isolated. In one animal (26) 
the KP isolate was initially typed as DHA-1, CTX-M-1/− 3/− 5 and as 
DHA-1 in later samples. All 4 KP isolates from this animal belonged to 
the same REP-PCR group (A). In three further animals, KP isolates (DHA- 
1, n = 2; CTX-M-1/− 3/− 5, n = 1) with the same REP-PCR profiles were 
Table 1 
Demographic and treatment data of dogs and cats included in the follow-up and 
the co-carriage study.  
Parameter Dogs (n =
28) 
Cats (n = 9) 
Median age; years (IQR) 6.5 (4.8–8) 9 
(4.3–12.2) 
Median weight; kg (IQR) 15.2 
(16–28.2) 
4.8 (4–5.4) 
Sex   
Female (entire/neutered) 8/6 0/2 
Male (entire/neutered) 5/9 0/7 
Diagnoses   
Gastrointestinal disease 6 2 
Neurological disease 7 1 
Urinary tract disease 1 3 
Orthopedic/traumatic disease 5 1 
Endocrine disease 1 0 
Dermatologic disease 1 0 
Infectious disease 2 0 
Immune-mediated disease 2 0 
Unknown 2 1 
Other 1 1 
MDRO status at presentation (pos/neg; n) 8/20 2/7 
Hospitalized (yes/no) 27/1 8/1 
Hospitalization days; median (IQR) 3 (2.5–3.7) 3.5 
(1.6–6.4) 
Admitted to ICU (yes/no) 15/9 4/4 
ICU days; median (IQR) 2 (1.6–3.3) 4.5 
(0.3–9.9) 
Antimicrobial treatment during hospitalization 
(yes/no) 
21/6 6/2 
Antimicrobials used during hospitalisationa   
Amoxicillin/clavulanic acid 2 3 
Ampicillin/sulbactam 6 3 
Cefazolin 7 0 
Cephalexin 1 0 
Clindamycin 2 0 
Doxycycline 1 0 
Enrofloxacin 4 0 
Marbofloxacin 0 1 
Metronidazole 1 0 
TMP-S 1 0 
Antimicrobials used after discharge (yes/no) 11/16 6/2 
Amoxicillin/clavulanic acid 5 6 
Cephalexin 2 0 
Clindamycin 1 0 
Doxycycline 1 0 
Enrofloxacin 2 0 
Median duration of antimicrobial treatment post 
discharge; days (IQR) 
7 (4.1–10.9) 8 
(3.8–12.2) 
ICU: intensive care unit; IQR: interquartile range; TMP-S: Trimethoprim/ 
sulfamethoxazole. 
a Includes mono- and combination therapy. 
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Fig. 2. Duration of carriage of multidrug-resistant organisms in dogs, cats and their respective owners. Only dogs and cats which were colonized with genetically 
related isolates beyond 30 days are shown. For a graphical overview of all cases included in the follow-up study see Supplemental Figs. 1–3. 
P: Presentation; D: Discharge. 
Red symbols: MDRO isolated. 







Abbreviations: CP: carbapenemase-producing; ESBL: extended spectrum β-lactamase-producing; E. coli: Escherichia coli; KP: Klebsiella pneumoniae; E. cloacae: 
Enterobacter cloacae; MR: Methicillin-resistant; S.: Staphylococcus 
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repeatedly isolated. 
3GC-R-E. coli were isolated repeatedly in 6 animals. In two animals 
(67; 255) repeated isolates showed different REP-PCR profiles. In the 
remaining 4 animals, hospital-acquired isolates that were repeatedly 
isolated from the same individual after discharge shared common REP- 
PCR profiles and ESBL/Plasmid-encoded AmpC (pAmpC) genes (CTX-M- 
9/− 14; CMY-42, CTX-M-1/− 3/− 15). In 2 animals hospital-acquired 
OXA-181-producing E. coli was repeatedly isolated (76; 96) [10]. 
3.1.7. Co-carriage of humans and pets 
16/50 (32%; 95%CI, 19.5–46.7) owners sampled themselves at the 
time of presentation of their animal to a veterinary practice or clinic and 
34/50 (68%; 95%CI, 53.3–80.5) after discharge of their pet. Twelve 
owners decided to submit samples only after their own animal had 
tested positive for MDRO on one or several occasions leading to delayed 
submissions. 
Twenty-one owner-pet pairs with owner and/or pet carrying MDRO 
were followed for up to 152 days (median 79; range 0–152 days, IQR 49) 
accumulating 1622 days of contact between MDRO carrying pets and/or 
owners. No co-carriage of MDRO was documented in repeated samples. 
In two cases (69 and 94), owner and dog carried both an ESBL-E. coli but 
those isolates where not genetically related (69, owner: CTX-M-55, 
ST95; dog: CTX-M-1/-3/-15 at presentation and CTX-M-9/− 14 at 
discharge and follow-up. 94, owner: CTX-M-55, ST1193; dog: CMY-42, 
ST410). Representative cases from the co-colonization study are 
shown in Figs. 2 and 3. A graphical overview of all cases included in the 
co-colonization study are shown in Supplemental Figs. 1 and 2. 
4. Discussion 
We previously reported a very high rate of acquisition of MDROs by 
dogs and cats treated in veterinary hospitals [11] and documented an 
outbreak of OXA-181-producing E. coli in one of the participating hos-
pitals [10]. In this part of the study, we described the duration of MDRO 
carriage in a subset of dogs and cats from the original study and assessed 
their owners for potential MDRO co-carriage at the time of admission of 
their pet and during a follow-up period in order to document potential 
transmission events. 
The results of this study document enteric colonization of dogs and 
cats with 3GC-R-KP for up to 136 days and for 3GC-R-E. coli for up to 
101 days. While 18% of participating owners carried MDROs, co- 
carriage or interspecies transmission of MDRO between animals and 
their owners was not demonstrated in the 21 pet-owner pairs that were 
followed up. 
In this cohort of pet owners, the proportion of MDRO positivity and 
in particular the proportion of owners with enteric carriage of 3GC-R- 
E. coli (10%) was in the upper range of what has been reported. Previous 
studies conducted in Switzerland demonstrated a prevalence of carriage 
of 5.6–10% for 3GC-R-Ent. in healthy volunteers [28], 1.5% for COL-R 
Enterobacterales in healthy and primary care patients [29] and 4.2% 
for 3GC-R-E. coli in owners of healthy pets [12]. While the number of 
participating owners was small, the relatively high positivity rate might 
reflect the worldwide rise in the prevalence of colonization of healthy 
humans with MDR E. coli and other Enterobacterales [28,30]. 
All human E. coli isolates had an ESBL/AmpC-positive genotype 
(blaCTX-M-55, blaCTX-M-15, blaCTX-M-1). In addition to their extended- 
spectrum cephalosporin resistance, two thirds of the isolates were 
resistant to ß-lactam antimicrobials, two thirds to trimethoprim/sulfa-
methoxazole (TMP–S) and one third each to aminoglycosides, fluo-
roquinolones and tetracyclines. While the resistance to many first line 
antimicrobials is problematic, none of the isolates showed resistance to 
carbapenems or colistin. Since their first isolation in the 1980s, isolates 
of the blaCTM-X ESBL genotype have become widespread internationally 
accounting for over 90% of ESBL-producing strains from community 
individuals [31]. CTX-M-producing E. coli have been commonly identi-
fied in Switzerland from various sources including from water of rivers 
and lakes [29], poultry, cattle and pigs at slaughter [32]. 
No specific risk factors for MDRO carriage in owners were identified, 
but the power of this analysis is low due to a small number of partici-
pants. Review of individual questionnaires of owners carrying MDRO 
did not confirm any of the known risk factors such as previous antimi-
crobial use [30], recent hospitalization (≤12 months) [33], or interna-
tional travel [30]. We assume that due to the widespread dissemination 
of ESBL-E. coli, there are now many routes for humans to get in contact 
with MDROs and the absence of risk factors no longer suggests absence 
of colonization. 
Based on the previous findings of a very high acquisition rate of 
MDROs in dogs and cats in veterinary care and the clonal dissemination 
of OXA-181-producing E. coli in one clinic, we aimed to follow their 
persistence and possible co-colonization in pet-owner pairs. While in the 
majority of pets MDRO carriage was no longer demonstrated at recheck, 
3 dogs and 4 cats showed prolonged enteric carriage of ESBL-KP for up to 
139 days and ESBL-E. coli for up to 101 days. No persistence was shown 
for Gram-positive MDROs. 
The durations of colonization in pets in this study are similar to what 
has been described in humans in long-term care (median 144 days 
(range, 41–349 days)) [34]. Studies in human new-borns (12.5 months 
(IQR 9.5–17.5)) [35] and adult patients post hospitalization report much 
longer durations of carriage (median of 58 months (range 41–59 
months)) [36]. In contrast, colonization in healthy returning travellers 
appeared to be much shorter (<3 months) [37,38]. 
The long-term enteric colonization of pets is problematic, as pets 
typically use litter boxes or defecate in gardens, parks and walking areas, 
and thus directly contaminate the close environment of humans 
[39–41]. Furthermore, cleaning of the cat litter boxes or picking up of 
faeces from the ground, may directly expose owners to MDROs. 
Grooming behaviours may lead to colonization of the oral cavity, fur and 
skin, from where MDROs can be transmitted to owners via petting, 
cuddling, licking of the owner’s face or hands or eating from the owner’s 
plate. In a recent questionnaire-based study such highly intense contact 
was reported to occur at least occasionally in over 90% of households 
[4]. 
All dogs and cats included in this study were family animals living in 
close contact with their owners as they shared living quarters and the 
large majority also the owner’s bed. Despite this close relationship, there 
was no evidence of any co-colonization in this study population. 
Transmission of MDROs between companion animals and their owners 
has previously been reported to occur in 1.5–5.5% of pet-owning 
households [8,12,42]. In contrast, intra-household transmission be-
tween hospitalized patients and their family members (40% [43] and 
18.5% [44]) and between infants and adults (32% [35]) has been found 
to be much higher presumably due to a more intense contact between 
humans as between pets and humans. 
While no pet-owner co-colonization was identified, we recently re-
ported the co-colonization of pets and veterinary staff by CR-E. coli, 
suggesting that interspecies transmission at the respective clinics is 
possible [45]. 
Limitations of this study include the relatively small number of pet- 
owner pairs, the irregular sampling intervals and the fact that owners 
were only sampled 1–2 times if negative. Given the low sensitivity of 
bacterial culture, more samples would be necessary to achieve a higher 
sensitivity of the methods for detecting MDROs [46]. For the follow-up, 
owners were sampling their own pets and, despite detailed instructions, 
it is possible that the sampling technique in particular with regards to 
the nasal sampling retrieved insufficient material to demonstrate 
carriage. 
In conclusion, dogs and cats requiring hospitalization may carry 
3GC-R-Ent. for several months. While MDRO carriage was common in 
pet owners, co-carriage or interspecies transmission of MDROs between 
animals and their owners was not demonstrated, despite close owner-pet 
relationships. 
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Fig. 3. Representative cases from the co-colonization 
study. While several owner-pet pairs showed coloni-
zation with multidrug-resistant organisms, co- 
colonization with genetically related organisms was 
not detected in any of the 21 owner-pet paires in the 
study. 
For a graphical overview of all cases included in the 
co-colonization study see supplemental Figs. 1 and 2. 
P: Presentation; D: Discharge. 
Red symbols: MDRO isolated. 
Green symbols: no MDRO isolated. 
Open symbol: no sample analyzed. (For interpretation 
of the references to colour in this figure legend, the 
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